Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 147Gynecologic 3Genitourinary 3Thoracic 2Head & Neck 2Dermatologic 2Breast 2

Conditions

Endometrial Neoplasms 19Ovarian Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Advanced Endometrial Cancer 2Adenocarcinoma 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Diseases 1Ovarian Clear Cell Carcinoma 1Neoplasms, Glandular and Epithelial 1Melanoma 1Liver Neoplasms 1

Interventions

pembrolizumab 20Nivolumab 10Cyclophosphamide 10atezolizumab 6Specimen Handling 6fludarabine 5Magnetic Resonance Spectroscopy 5cabozantinib 4Ipilimumab 4Bevacizumab 4lenvatinib 3X-Rays 3Trastuzumab 3Paclitaxel 3Oxaliplatin 3Immunoglobulin G 3Fluorodeoxyglucose F18 3ulixertinib 2sargramostim 2poly ICLC 2epacadostat 2enzalutamide 2durvalumab 2cemiplimab 2budigalimab 2avelumab 2aldesleukin 2aflibercept 2Sirolimus 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × lenvatinib × Gynecologic × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

Phase 1/2 Active not recruiting
263 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡